

The Republic of Kyrgyzstan

Support for Vaccine: Pentavalent

This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	The Republic of Kyrgyzstan																							
2. Vaccine grant number:	0708-KGZ-03a-X; 0910-KGZ-04a-X; KGZ-Lumpsum-1; 08-KGZ-08b-Y, 1115-KGZ-04a-X, 1115-KGZ-04C-X, 16-KGZ-04a-X, 17-KGZ-04a-X, 1821-KGZ-04a-X																							
3. Date of Decision Letter:	30-Sep-2019																							
4. Date of the Partnership Framework Agreement:	5/16/2014																							
5. Programme title:	New Vaccine Support (NVS), DTP-HepB-Hib, Routine																							
6. Vaccine type:	DTP-HepB-Hib																							
7. Requested product presentation and formulation of vaccine:	Penta, 1 dose per vial, LIQUID																							
8. Programme Duration:¹	2001-2021																							
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement)																							
	2001-2019	2020	2021	Total ²																				
Programme Budget (US\$)	10,999,142	39,500	452,000	11,490,642																				
10. Vaccine introduction grant	<table border="1"> <thead> <tr> <th colspan="3">Approval</th> </tr> <tr> <th>Year</th> <th>Grant Number</th> <th>Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td>2001</td> <td>KGZ-Lumpsum-1</td> <td>100,000</td> </tr> <tr> <td>2008</td> <td>08-KGZ-08b-Y</td> <td>100,000</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th colspan="2">Disbursement</th> </tr> <tr> <th>Disbursement date</th> <th>Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td>30 December, 2002</td> <td>100,000</td> </tr> <tr> <td>13 January, 2009</td> <td>100,000</td> </tr> </tbody> </table>				Approval			Year	Grant Number	Amount (US\$)	2001	KGZ-Lumpsum-1	100,000	2008	08-KGZ-08b-Y	100,000	Disbursement		Disbursement date	Amount (US\$)	30 December, 2002	100,000	13 January, 2009	100,000
Approval																								
Year	Grant Number	Amount (US\$)																						
2001	KGZ-Lumpsum-1	100,000																						
2008	08-KGZ-08b-Y	100,000																						
Disbursement																								
Disbursement date	Amount (US\$)																							
30 December, 2002	100,000																							
13 January, 2009	100,000																							
11. Product switch grant	Not applicable																							
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement)																							
Type of supplies to be purchased with Gavi funds	2001-2019	2020	2021																					

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

Number of vaccine doses		32,000	-		
Annual Amounts (US\$)	10,999,142	39,500	-		
13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.					
14. Self-procurement: Not applicable					
15. Co-financing obligations: According to the co-financing policy, the Country falls within the group: Preparatory transition phase The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.					
Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024
Number of vaccine doses	7,700	105,700	-	-	-
Number of AD syringes	8,100	110,700	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	100	1,225	-	-	-
Value of vaccine doses (US\$)	8,918	122,502	-	-	-
Total co-financing payments (US\$) (including freight)	10,000	135,000	-	-	-
16. Operational support for campaigns: Not applicable					
17. Additional Reporting Requirements:					
					Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:					
<ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 					31 March 2020 15 May 2020
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.					To be agreed with Gavi Secretariat
18. Financial clarifications: Not applicable					
19. Other conditions: Not applicable					

Signed by,

On behalf of Gavi



Thabani Maphosa,
Managing Director, Country Programmes
30-Sep-2019